Recent Updates
Recently added Catalysts
ONC Positive Sentiment

Samenvatting: BeOne Medicines, BeOne Care Foundation en The Max Foundation verlengen samenwerking om toegang tot BRUKINSA® voor de behandeling van chronische lymfatische leukemie in lage- en middeninkomenslanden te vergroten

Tuesday, August 18, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: BeOne Medicines, along with the BeOne Care Foundation and The Max Foundation, has announced the extension of their collaboration until 2028. This partnership aims to enhance access to BRUKINSA® (zanubrutinib) for treating chronic lymphocytic leukemia in low- and middle-income countries. The initiative reflects a commitment to improving healthcare accessibility.

Market Sentiment Analysis

POSITIVE FACTORS

  • Collaboration extended until 2028.
  • Increased access to BRUKINSA® for patients.
  • Focus on low- and middle-income countries.
  • Partnership with reputable organizations.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+15%
120-day peak, hindsight
Typical move
3.8%
average across 5 past catalysts
Lead asset
Tislelizumab
Phase 3 · Non-small Cell Lung Cancer

Full Press Release Details

SAN CARLOS, Calif. & SEATTLE--(BUSINESS WIRE)--BeOne Medicines Ltd. ('BeOne') (Nasdaq: ONC; HKEX: 06160; SSE: 688235), een wereldwijd oncologiebedrijf, heeft vandaag – samen met de BeOne Care Foundation, een non-profit liefdadigheidsstichting, en The Max Foundation, een toonaangevende internationale non-profitorganisatie op het gebied van gezondheidszorg – de verlenging aangekondigd van hun samenwerking tot en met 2028. Het doel is om de toegang tot BRUKINSA® (zanubrutinib) voor de behandeling

Frequently Asked Questions

What is the purpose of the partnership extension?

The partnership aims to enhance access to BRUKINSA® for treating chronic lymphocytic leukemia.

Who are the partners involved in this collaboration?

The partners include BeOne Medicines, BeOne Care Foundation, and The Max Foundation.

Until when is the partnership extended?

The partnership has been extended until 2028.

Which countries will benefit from this initiative?

The initiative focuses on low- and middle-income countries.

ShareAdd on Google
Tags: ONC Viatris Investor Conferences Healthcare BeOne Medicines BRUKINSA zanubrutinib chronic lymphocytic leukemia healthcare access
Last updated: Aug 18, 2026

Biotech snapshot

Cash runway
$5098M liquidity · $0M/mo burn
Low dilution risk
Lead asset
TislelizumabPhase 3
Non-small Cell Lung Cancer →

Catalyst track record

+15%
best trade around ONC's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for ONC.

See every catalyst's timing & PoA →